ストックスクリーナーアプリを入手
24.09
2.62%
0.615
アフターアワーズ：
24.50
0.41
+1.70%
前日終値:
$23.48
開ける：
$23.49
24時間の取引高:
254.84K
Relative Volume:
0.54
時価総額：
$836.98M
収益：
$154.15M
当期純損益:
$-33.58M
株価収益率:
-25.09
EPS:
-0.96
ネットキャッシュフロー:
$-20.74M
1週間 パフォーマンス:
+2.42%
1か月 パフォーマンス:
+5.20%
6か月 パフォーマンス:
-52.49%
1年 パフォーマンス:
+82.64%
1日の値動き範囲:
$22.55
$24.19
1週間の範囲:
$20.85
$25.26
52週間の値動き範囲:
$9.86
$59.23
Harrow Inc Stock (HROW) Company Profile
HROW を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
24.09 | 836.98M | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
149.44 | 65.57B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.88 | 43.81B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.06 | 43.47B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.46 | 15.42B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
281.16 | 12.53B | 2.76B | 1.11B | 898.10M | 22.77 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-04 | 繰り返されました | B. Riley Securities | Buy |
| 2024-04-11 | 開始されました | Craig Hallum | Buy |
| 2022-09-08 | 再開されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2021-09-24 | 開始されました | Aegis Capital | Buy |
| 2021-07-02 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Harrow Inc (HROW) 最新ニュース
Major Dry Eye Treatment Breakthrough: VEVYE Opens Access to 25,000+ Patients with $59 Price Tag - Stock Titan
Where Harrow Stands With Analysts - Benzinga
B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating - MarketScreener
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives By GuruFocus - Investing.com Canada
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance
Harrow Health Reports Strong 2024 Financial Performance - TipRanks
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha
Harrow Health (HROW) Gets a Buy from Craig-Hallum - The Globe and Mail
Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Harrow: Q4 Earnings Snapshot - The Advocate
Harrow Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Joplin Globe
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 - Business Wire
Harrow Inc. sees $150k stock sale by Opaleye Management - Investing.com
Harrow Inc (HROW) Shares Gap Down to $27.235 on Mar 26 - GuruFocus
Harrow sees shares increase following drug approval - Nashville Post
Craig-Hallum Reaffirms Their Buy Rating on Harrow Health (HROW) - The Globe and Mail
CMS approves separate reimbursement for Harrow’s TRIESENCE - Investing.com
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire
TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan
Harrow Inc (HROW) Shares Up 1.14% on Mar 22 - GuruFocus
Opaleye management sells $148,200 in Harrow, Inc. stock - Investing.com India
What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus
Opaleye Management Inc. Adjusts Stake in Harrow Inc. - GuruFocus
Bank of New York Mellon Corp Has $2.90 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Shares Up 2.97% on Mar 21 - GuruFocus
Opaleye management sells $148,200 in Harrow, Inc. stock By Investing.com - Investing.com South Africa
Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha
H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target - Investing.com India
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial - GlobeNewswire Inc.
Harrow stock surges on preliminary Q4 numbers - Nashville Post
Sector Update: Health Care -March 18, 2025 at 08:49 am EDT - Marketscreener.com
Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga India
Harrow Reports Preliminary 2024 Q4 and Full-Year Financial Results, Provides 2025 Guidance and Launches New Initiative - VisionMonday.com
Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus.com
Harrow Completes Transfer of the TRIESENCE® New Drug Application - Business Wire
Harrow Reports Q4 Preliminary Revenue -- Shares Rise After Hours -March 17, 2025 at 04:30 pm EDT - Marketscreener.com
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance - Business Wire
Harrow Launches VEVYE® Access for All - Business Wire
Harrow Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Nasdaq
Harrow Inc (HROW) 財務データ
収益
当期純利益
現金流量
EPS
1.03%
1.54%
大文字化:
|
ボリューム (24 時間):